CLGN
CollPlant Biotechnologies Ltd.
$2.16
-$0.03(-1.37%)
26
Overall
--
Value
10
Tech
42
Quality
Market Cap
$26.46M
Volume
27.42K
52W Range
$1.31 - $4.98
Target Price
$11.50
Order:
Income Statement
| Metric | Trend | Chart | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||
| Total Revenue | $1.7M | $5.0M | $2.3M | $6.1M | $15.6M | $299.0K | $11.0M | $515.0K | ||
| Total Revenue | $1.7M | $5.0M | $2.3M | $6.1M | $15.6M | $299.0K | $11.0M | $515.0K | ||
| COST OF GOODS SOLD | ||||||||||
| Cost of Revenue | $-52.0K | $1.7M | $1.9M | $3.0M | $-2.0M | $-400.0K | $2.0M | $1.6M | ||
| GROSS PROFIT | ||||||||||
| Gross Profit | $1.6M | $3.4M | $439.0K | $3.1M | $13.6M | $-101.0K | $9.0M | $-1.1M | ||
| OPERATING EXPENSES | ||||||||||
| Operating Expenses | $25.6M | $9.8M | $8.1M | $8.7M | $13.6M | $17.0M | $16.5M | $16.1M | ||
| Research & Development | $16.9M | $3.9M | $4.4M | $4.1M | $7.6M | $10.3M | $10.5M | $10.5M | ||
| Research Expense | $16.9M | $3.9M | $4.4M | $4.1M | $7.6M | $10.3M | $10.5M | $10.5M | ||
| Selling, General & Administrative | $8.7M | $3.7M | $3.7M | $4.7M | $5.9M | $6.7M | $6.0M | $5.6M | ||
| Selling & Marketing Expenses | $8.7M | $3.7M | $3.7M | -- | -- | -- | -- | -- | ||
| General & Administrative Expenses | -- | $-331.0K | $3.7M | $4.7M | $5.9M | $6.7M | $6.0M | $5.6M | ||
| Salaries & Wages | $-2.0M | $-2.1M | -- | $-1.9M | -- | $-2.6M | -- | -- | ||
| Depreciation & Amortization | -- | $2.2M | $-539.0K | $-660.0K | -- | -- | -- | -- | ||
| Depreciation & Amortization | -- | $2.2M | $-539.0K | $-660.0K | -- | -- | -- | -- | ||
| Amortization | -- | -- | -- | -- | -- | $-1.0M | -- | -- | ||
| Other Operating Expenses | $-2.3M | $-1.3M | $-3.3M | $-795.0K | -- | $-9.0K | -- | -- | ||
| OPERATING INCOME | ||||||||||
| Operating income | $-24.0M | $-6.4M | $-7.6M | $-5.6M | $65.0K | $-17.1M | $-7.5M | $-17.3M | ||
| EBITDA | $-23.7M | $-4.6M | $-10.6M | $-5.1M | $1.0M | $-15.8M | $-5.9M | $-15.6M | ||
| NON-OPERATING ITEMS | ||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | -- | -- | $10.0K | -- | ||
| Interest Income Operating | -- | -- | -- | -- | -- | -- | $493.0K | $642.0K | ||
| Intinc | $253.0K | $1.6M | -- | $-175.0K | $172.0K | $172.0K | $788.0K | -- | ||
| Net Non-Operating Interest Income/Expense | $253.0K | $1.6M | -- | $-175.0K | $172.0K | $172.0K | $778.0K | -- | ||
| Gain on Sale of Securities | -- | -- | -- | $40.0K | -- | -- | -- | -- | ||
| Other Income/Expense | $-32.4M | $-9.9M | $3.5M | $-23.0K | $-7.0K | $-24.0K | $-285.0K | -- | ||
| Other Special Charges | $32.4M | $9.9M | $-3.5M | $23.0K | $7.0K | $24.0K | -- | -- | ||
| SPECIAL ITEMS | ||||||||||
| Restructring And Mn A Income | -- | $225.0K | -- | -- | -- | -- | -- | -- | ||
| Special Income Charges | -- | $-225.0K | $44.0K | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||
| EBIT | $-23.7M | $-6.8M | $-11.2M | $-5.8M | $237.0K | $-16.9M | $-7.0M | $-16.6M | ||
| Pre-Tax Income | $-23.7M | $-6.8M | $-11.2M | $-5.8M | $237.0K | $-16.9M | $-7.0M | $-16.6M | ||
| INCOME TAX | ||||||||||
| Tax Provision | -- | -- | -- | -- | -- | -- | -- | -- | ||
| NET INCOME | ||||||||||
| Net Income | $-23.7M | $-6.8M | $-11.2M | $-5.8M | $237.0K | $-16.9M | $-7.0M | $-16.6M | ||
| Net Income (Continuing Operations) | $-23.7M | $-6.8M | $-11.2M | $-5.8M | $237.0K | $-16.9M | $-7.0M | $-16.6M | ||
| Net Income (Discontinued Operations) | $-23.7M | $-6.8M | $-11.2M | $-5.8M | $237.0K | $-16.9M | $-7.0M | $-16.6M | ||
| Net Income (Common Stockholders) | $-23.7M | $-6.8M | $-11.2M | $-5.8M | $237.0K | $-16.9M | $-7.0M | $-16.6M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | $-5.2M | $-16.4M | ||
| TOTALS | ||||||||||
| Total Expenses | $25.6M | $11.4M | $9.9M | $11.7M | $11.6M | $16.6M | $18.5M | $17.8M | ||
| SHARE & EPS DATA | ||||||||||
| Average Shares Outstanding | $133.2M | $4.4M | $5.0M | $6.9M | $10.0M | $11.0M | $11.4M | $11.5M | ||
| Average Shares Outstanding (Diluted) | $148.3M | $4.4M | $5.0M | $6.9M | $12.0M | $11.0M | $11.4M | $11.5M | ||
| Shares Outstanding | $166.8M | $190.7M | $5.7M | $7.0M | $10.8M | $11.2M | $11.5M | $11.5M | ||
| Basic EPS | $0.16 | $1.43 | $2.23 | $-0.84 | $0.02 | $-1.53 | $-0.62 | $-1.45 | ||
| Basic EPS (Continuing Operations) | -- | $1.43 | $2.23 | $-0.84 | -- | -- | $-0.62 | $-1.45 | ||
| Diluted EPS | -- | $1.43 | $2.23 | $-0.84 | $0.02 | $-1.53 | $-0.62 | $-1.45 | ||
| Diluted EPS (Continuing Operations) | -- | -- | $2.23 | $-0.84 | -- | -- | $-0.62 | $-1.45 | ||
| OTHER METRICS | ||||||||||
| Commission Expenses | $380.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Other Costof Revenue | -- | -- | -- | -- | -- | -- | $2.0M | $1.6M | ||
| Other Gand A | -- | $-331.0K | $3.7M | $4.7M | $5.9M | $6.7M | $6.0M | $5.6M | ||
| Rent And Landing Fees | -- | $-331.0K | $-619.0K | $-633.0K | $5.9M | $6.7M | -- | -- | ||
| Selling Expense | $8.3M | $3.7M | $3.7M | -- | -- | -- | -- | -- | ||
| Write Down | -- | -- | $-44.0K | -- | -- | -- | -- | -- | ||
| Restruct | -- | $225.0K | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CLGN | $2.16 | -1.4% | 27.42K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get CollPlant Biotechnologies Ltd. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW